Agios Pharmaceuticals

- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 386
- Market Cap
- $2.6B
- Website
- http://www.agios.com
- Introduction
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Clinical Trials
140
Trial Phases
5 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (130 trials with phase data)• Click on a phase to view related trials
A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT07075640
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Madison, Wisconsin, United States
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: Tebapivat Matched Placebo
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06924970
- Locations
- 🇺🇸
UConn Health, Farmington, Connecticut, United States
🇺🇸University of Texas Health Science Center of Houston, Houston, Texas, United States
🇧🇪Clinique CHC MontLégia, Liège, Wallonne, Belgium
A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: [13C2,15N3]-tebapivat
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06745271
- Locations
- 🇺🇸
Taha El-Shahat, Madison, Wisconsin, United States
Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06648824
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States
A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease
- Conditions
- Sickle Cell Disease (SCD) and Nephropathy
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Agios Pharmaceuticals Inc.
- Target Recruit Count
- 17
- Registration Number
- 2023-510289-28-00
- Locations
- 🇮🇪
St James's Hospital, Dublin 8, Ireland
🇫🇷Oncopole Claudius Regaud, Toulouse Cedex 9, France
🇫🇷Hospices Civils De Lyon, Lyon Cedex 03, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
New Report Analyzes 1,775 Clinical-Stage Pharma Partnerships from 2020-2025
ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.
Schrödinger Discontinues Blood Cancer Drug SGR-2921 After Two Patient Deaths in Phase I Trial
Schrödinger has terminated development of its CDC7 inhibitor SGR-2921 after two patient deaths in a Phase I trial for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Agios Pharmaceuticals Faces FDA Delay for Pyrukynd Thalassemia Approval Amid Safety Concerns
The FDA has extended the review period for Agios Pharmaceuticals' Pyrukynd (mitapivat) in thalassemia, pushing the PDUFA date from September 7, 2025 to December 7, 2025 due to a required Risk Evaluation and Mitigation Strategy (REMS) submission.
Avanzanite Partners with Agios to Commercialize First-in-Class Pyruvate Kinase Activator Across Europe
Avanzanite Bioscience has secured exclusive European commercialization rights for PYRUKYND® (mitapivat), a first-in-class pyruvate kinase activator approved for treating adults with PK deficiency.
Sickle Cell Disease Pipeline Shows Robust Growth with 60+ Therapies in Development Across Multiple Clinical Phases
DelveInsight's 2025 assessment reveals a robust sickle cell disease pipeline with 55+ companies developing 60+ therapeutic candidates across various clinical development stages.
Halda Therapeutics Appoints Dr. Eyal Attar as Chief Medical Officer to Advance Novel RIPTAC Cancer Platform
• Dr. Eyal Attar joins Halda Therapeutics as Chief Medical Officer, bringing over 25 years of biotechnology R&D and clinical trial experience to advance the company's novel RIPTAC cancer therapy platform. • Halda is currently conducting a Phase 1/2 clinical trial of HLD-0915, their lead candidate targeting metastatic castration-resistant prostate cancer (mCRPC) through a unique "hold and kill" mechanism designed to overcome resistance. • The RIPTAC platform represents a new therapeutic modality that creates neomorphic protein-protein interactions to selectively target cancer cells, with programs in development for prostate cancer, breast cancer, and other serious diseases.
Agios' Mitapivat Achieves Primary Endpoint in Phase 3 Trial for Children with PK Deficiency
Mitapivat demonstrated significant efficacy in the ACTIVATE-Kids Phase 3 trial, becoming the first oral therapy to show positive results in children with non-transfusion-dependent PK deficiency.
Agios Pharmaceuticals Advances Tebapivat for Sickle Cell Disease and Hemolytic Anemias
Agios Pharmaceuticals is developing Tebapivat (AG-946), an oral PKR activator, targeting multiple hemolytic anemic conditions including sickle cell disease and PK deficiency.
European Commission Grants Orphan Drug Designation to Agios' Mitapivat for Sickle Cell Disease
The European Commission has granted orphan medicinal product designation to mitapivat for the treatment of sickle cell disease, offering benefits like reduced fees and market exclusivity.
Vorasidenib Confirms Efficacy and Safety in IDH1/2-Mutant Diffuse Glioma
Updated data from the phase 3 INDIGO study demonstrates vorasidenib's continued efficacy in patients with IDH1/2-mutated diffuse glioma.